MAD2L1 Antibody

中文名稱：

MAD2L1兔多克隆抗體
貨號：

CSB-PA619756LA01HU
規格：

￥440
圖片：
IHC image of CSB-PA619756LA01HU diluted at 1:400 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

IHC image of CSB-PA619756LA01HU diluted at 1:400 and staining in paraffin-embedded human cervical cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) MAD2L1 Polyclonal antibody
Uniprot No.：

Q13257
基因名：

MAD2L1
別名：

HsMAD2 antibody; MAD 2 antibody; MAD2 like 1 antibody; MAD2 mitotic arrest deficient like 1 antibody; MAD2-like protein 1 antibody; Mad2l1 antibody; MD2L1_HUMAN antibody; Mitotic arrest deficient 2-like protein 1 antibody; Mitotic spindle assembly checkpoint protein MAD2A antibody; REV7 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Mitotic spindle assembly checkpoint protein MAD2A protein (2-205AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，MAD2L1 Antibody (CSB-PA619756LA01HU)，的標記方式是Non-conjugated。對于MAD2L1 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA619756LB01HU	MAD2L1 Antibody, HRP conjugated	ELISA
FITC	CSB-PA619756LC01HU	MAD2L1 Antibody, FITC conjugated
Biotin	CSB-PA619756LD01HU	MAD2L1 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:200-1:500

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Component of the spindle-assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate. In the closed conformation (C-MAD2) forms a heterotetrameric complex with MAD1L1 at unattached kinetochores during prometaphase, the complex recruits open conformation molecules of MAD2L1 (O-MAD2) and then promotes the conversion of O-MAD2 to C-MAD2. Required for the execution of the mitotic checkpoint which monitors the process of kinetochore-spindle attachment and inhibits the activity of the anaphase promoting complex by sequestering CDC20 until all chromosomes are aligned at the metaphase plate.
基因功能參考文獻：
1. MAD2 was found both in SCLC and NSCLC. Interestingly, there was a significant difference found between SCLC and NSCLC using qt-PCR (P<0.05). PMID: 30346937
2. we demonstrate that the CDC20-MAD2 complex could also be formed independently of the SAC. Moreover, in prolonged arrest caused by nocodazole treatment, the overall levels of the CDC20-MAD2 complex are gradually, but significantly, reduced and this is associated with lower levels of cyclin B1, which brings a new insight into the mechanism of mitotic "slippage" of the arrested cells. PMID: 28112196
3. MAD2-p31(comet) axis may serve as a potential therapeutic target for glioma. PMID: 29408509
4. These results identify an unexpected dependency on TRIP13 in cells overexpressing Mad2. PMID: 28564602
5. this study shows that MAD2L1 is a prognostic biomarker for lung adenocarcinoma PMID: 27835911
6. MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma by suppressing MAD2L1 expression. PMID: 28609841
7. Low MAD2L1 expression is associated with Chromophobe Renal Cell Carcinomas. PMID: 28807937
8. TRAP1 is relevant in the control of key cell cycle regulators in tumor cells. TRAP1/TBP7 quality control of CDK1 and MAD2 contributes mechanistically to the regulation of mitotic entry and transit. PMID: 28678347
9. Thes authors show that p31(comet) binding to the TRIP13 N-terminal domain positions the disordered MAD2 N-terminus for engagement by the TRIP13 "pore loops", which then unfold MAD2 in the presence of ATP. PMID: 28659378
10. catalytic activation of the spindle assembly checkpoint depends on regulated protein-protein interactions that accelerate the spontaneous but rate-limiting conversion of MAD2 required for mitotic checkpoint complex assembly PMID: 28102834
11. in addition to its role in checkpoint signaling, MAD2 ensures chromosome stability through the regulation of AURORA B. PMID: 27341405
12. Overexpression of MAD2gamma may play a role in checkpoint disruption and is associated with resistance to cisplatin-based chemotherapy in testicular germ cell tumors. PMID: 27315568
13. Aberrant Mad2 expression was associated with cell proliferation and genetic instability, which may contribute to the carcinogenesis of PGI-DLBCL. Mad2 overexpression indicated a poor DFS. PMID: 27077767
14. interactions between Mad2 and H3K4 regulate resolution of the spindle assembly checkpoint by limiting closed Mad2 availability for Cdc20 inhibition. PMID: 27198228
15. we showed that BubR1 and Mad2 are overexpressed in oral squamous cell carcinoma cell lines and linked such overexpression to attenuated spindle assembly checkpoint activity. PMID: 25754611
16. Studied the folding/unfolding process of the open and closed conformers of human Mad2. PMID: 26489879
17. MAD1L1 Arg558His and MAD2L1 Leu84Met interaction with smoking increase the risk of colorectal cancer PMID: 26183163
18. p31comet-induced cell death is mediated by interactions with Mad2 PMID: 26544187
19. MAD2L1 and BUB1 may play important roles in breast cancer progression, and measuring the expression of these genes may assist the prediction of breast cancer prognosis. PMID: 26287798
20. We also show that replication perturbations result in relocalization of MAD1/MAD2 in human cells, suggesting that the role of SAC in DNA repair is conserved. PMID: 25898113
21. Data indicate the structure of the intermediate conformer of the multistate checkpoint protein mitotic arrest deficient 2 (Mad2) protein. PMID: 26305957
22. WT1 has a role in interacting MAD2 and regulating mitotic checkpoint function PMID: 25232865
23. In conclusion, the results presented here suggest that Mad2 and BubR1 could be used as prognostic markers of tumor progression and new pharmacological targets in the treatment for gastric cancer . PMID: 25483095
24. Co-depletion of MAD2 and BUBR1 causes cell cycle arrest and cell death in addition to aneuploidy. PMID: 24687487
25. hMAD2 also binds to the hREV7-binding sequence in hREV3, whereas hMAD2 does not bind to a similar sequence in ADAM9 or ELK-1 and hREV7 does not bind to the hMAD2-binding sequence in hMAD1 or hCDC20. PMID: 20088965
26. CDC20, MAD2 and Aurora-B protein expression are associated with chromosomal abnormalities and poor prognosis in patients with myelodysplastic syndromes. PMID: 25637637
27. the interaction of FAT10 with MAD2 is a key mechanism underlying the promalignant property of FAT10 PMID: 25422469
28. MAD2 and CDC20 overexpression was increased in high-grade squamous intraepithelial lesions and squamous cell carcinomas, suggesting their involvement in the initiation of cervical cancers. PMID: 25083970
29. MAD2 may be involved in oral carcinogenesis and may represent an important prognostic factor associated with a more malignant phenotype of oral squamous cell carcinoma. PMID: 25503128
30. This article reviews Mad1 and Mad2 - structural and functional relationship with implication in genetic diseases, specifically in cancer. [review] PMID: 24724894
31. The interconversion between two distinct conformations of open- and closed-states might facilitate the functional activity of the Mad2 protein. PMID: 24690997
32. Results showed that neither variants in BUB3 nor variants in MAD2L1 caused any significant effect on the risk of breast cancer PMID: 24711138
33. In ovarian carcinoma, tumors showing reduced nuclear MAD2 intensity identifying patients with a poorer recurrence-free survival prognosis. PMID: 24792619
34. The expression and localization of Mad2 and Cdc20 is regulated by subcellular Chk1 during the metaphase-anaphase transition. PMID: 24747134
35. MiR-28-5p is a critical regulator of Mad2 translation and mitotic checkpoint function. PMID: 24491803
36. attenuating the affinity of p31(Comet) for Mad2 by phosphorylation promotes SAC activity in mitosis. Specifically, phosphorylation of Ser-102 weakens p31(Comet)-Mad2 binding and enhances p31(Comet)-mediated bypass of the SAC. PMID: 24596092
37. Results show that Mad1-Mad2 must be targeted to nuclear pore complexes (NPCs) in order to produce the premitotic Cdc20 inhibitor, which ensures that anaphase and mitotic exit are robustly coupled to the establishment and correction of kinetochore-microtubule attachments. PMID: 24581499
38. results strongly suggest that PP2A is a good therapeutic target in Mad2-overexpressing tumors PMID: 24425774
39. Studied the significance of budding uninhibited by benzimidazoles-1 (Bub1) and mitotic arrest deficient-2 (Mad2) expression in endometrial carcinoma. PMID: 24654460
40. Tpr is a kinetochore-independent, rate-limiting factor required to mount and sustain a robust SAC response. PMID: 24344181
41. sustained MPS1 activity is required for maintaining both the MAD1.C-MAD2 complex and open MAD2 (O-MAD2) at unattached kinetochores to facilitate C-MAD2 production PMID: 24151075
42. increased expression of CDC20 and MAD2 is related to poor prognosis of urothelial carcinoma of the human bladder PMID: 23995871
43. Mad2 protein is co-localizes and associated with chk1 increase after DNA damage. PMID: 23454898
44. Mad2 Binding Induces a Functional Switch in Cdc20,Enabling BubR1 Binding. PMID: 23791783
45. MAD2 expression levels can indicate sensitivity to anticancer agents, and risk for recurrence in ovarian serous adenocarcinoma. PMID: 22797604
46. data validate the correlation between upregulation of Mad2 and osteosarcoma advancement, and that the underlying mechanisms involve the increase of invasiveness and cancer stem cell properties PMID: 22992948
47. Weakened spindle checkpoint with reduced expression of Mad2 is associated with resistance to paclitaxel in ovarian cells. PMID: 21063845
48. The germline transmission of exonic deletion of MAD2 is possibly associated with its loss of expression resulting in abnormal spindle assembly checkpoint function, subsequent aneuploidy and pregnancy loss. PMID: 22869558
49. The Mad2 and the APC/C competed for Cdc20 in vitro, and a Cdc20 mutant that does not bind stably to Mad2 abrogated the SAC in vivo. PMID: 23007648
50. The mitotic Checkpoint Complex is assembled by first forming a BUBR1:BUB3:CDC20 complex in G2 and then selectively incorporating MAD2 in the closed conformation during mitosis. PMID: 22037211
顯示更多

收起更多
亞細胞定位：

Nucleus. Chromosome, centromere, kinetochore. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole.
蛋白家族：

MAD2 family
數據庫鏈接：

HGNC: 6763

OMIM: 601467

KEGG: hsa:4085

STRING: 9606.ENSP00000296509

UniGene: Hs.591697

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human